Randomized trial · people
LL-37 cream: bigger granulation gains in diabetic foot ulcers
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a human trial, LL-37 cream improved a wound-healing measure in diabetic foot ulcers but did not lower inflammation markers or bacteria compared with placebo.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2023
- Journal
- Arch Dermatol Res
What they tested
The team tested whether LL-37 cream speeds healing of mildly infected diabetic foot ulcers and lowers inflammation markers and bacteria in the wound.
How the study was done
A randomized, double-blind, placebo-controlled trial in Jakarta, run from January 2020 to June 2021, in people with diabetic foot ulcers with mild infection. Patients put either LL-37 cream or a placebo (dummy) cream on the wound twice a week for 4 weeks, and wounds were measured on days 7, 14, 21 and 28.

What they found
Before treatment, both groups had similarly low LL-37 in their wound fluid: 1.07 (0.37-4.96) ng/mg protein in the LL-37 arm versus 1.11 (0.24-2.09) ng/mg protein in the placebo arm. The granulation index, a measure of new healing tissue in the wound, grew more in the LL-37 arm at every check: day 7 (p = 0.031), day 14 (p = 0.009), day 21 (p = 0.006) and day 28 (p = 0.037). In both arms, the inflammation markers IL-1α and TNF-α were higher by days 14 and 21, and the two arms did not differ significantly (p > 0.05). Aerobic bacteria counts dropped further with LL-37 through day 21 but further with placebo by day 28, and none of these gaps were significant (p > 0.05).
What it doesn’t show
The trial lasted only 4 weeks, in one city, and only included ulcers with mild infection. Its healing measure was granulation index, so it does not show whether wounds fully closed sooner.
The paper
Miranda et al. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res. 2023.
The compound
More studies on LL-37
- LL-37: no healing gain over placebo for venous leg ulcers overallRandomized trial · people · 2021
- LL-37 drove IL-1β and IL-18 release from human and murine macrophagesCell study · human and murine macrophages · 2013
- LL-37 raised TLR9 and interferon output in human skin cellsCell study · normal human keratinocytes · 2012
- Every study on LL-37
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.